Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You fit the narrative precisely... along with the rest of your paid ilk who FUD here daily. 👺🐀
“Congress has passed the first-ever federal bill dedicated to ending Parkinson’s! This historic legislation now heads to President Biden’s desk thanks to the tireless efforts of tens of thousands of policy advocates, champions in Congress, partner organizations and many others. We stand ready to work together to bring the promise of the National Plan to fruition on behalf of everyone touched by Parkinson’s and atypical parkinsonisms.” https://www.michaeljfox.org/
I will vote as per the recommendation of the BOD.
Good luck and GOD bless,
hi georgejj i have a question for you how are you going to vote for this year proxy.THANKS.JUST HOLD ON TIGHT LOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOONGS
I'll trade you 2 of my turds for your skunk and clown...
Yes, I know.
Good luck and GOD bless,
George, the AGM is June 18th.
ASM meeting is on the 18th of June 2024.
https://www.sec.gov/Archives/edgar/data/1314052/000173112224000732/e5643_defa14a.htm
Good luck and GOD bless,
When is the ASM ?
To not have or spread anxious fear. I stand firm in my investment while others cry and complain. How was that?
“No one needs to spread FUD to Anavex investors. Anavex is doing a great job of destroying the share price all on its own...”
Correct. The problem is it doesn’t fit bas2020’s preferred conspiracy theory/narrative. In bas2020’s world view, Missling/Anavex (one and the same) can do no wrong. Whatever happens, it’s always the fault of the nefarious, unseen, unknown and all powerful cabal.
Oh. Sure. I believe you. Thank you for the explanation. It makes perfect sense. I look forward to Anavex getting their first approval.
“Keep in mind a lot of these publications are funded by big pharma.”
That’s news to me. Please cite a credible source for this incredible statement.
What did you learn from them?
Scientists reveal the brain’s surprising role in regulating the immune system.
https://www.psypost.org/scientists-reveal-the-brains-surprising-role-in-regulating-the-immune-system/
I'm playing around with my next bids in the 3.85-3.70 area now. This also seems to be a price level related to the index listings. And funds forced to sell, etc. Small differences in price I pay, I'm only adding small amounts anyway, but I like to understand how the price moves to hit targets. I did not think 3.25 would be the lowest bottom back then, but maybe it could be.
For now, the MAA is like the peer review. It’s fake news until we see it.
Once we see it/them, sentiment will change rapidly.
"Paint the Tape" looked like maybe 50K shares. Puny quantity compared to last couple weeks.
Current afterhours current bids.
Bid 4.01 x by 200 Ask 4.08 x by 100 Total 794.68K for today includes the afterhours.
John k9uwa
"Um, George I show AVXL closing at $4.07" yes 4.07 the 4.01 was some afterhours trade. No large spike in shares traded afterhours today like we have seen near daily the last couple weeks. One day last week the afterhours jumped up the total for the day by around 40%.
John k9uwa
Leo good chance it will be a WHILE. I know define while ! Whenever they have something of substance. I can give them a good one to use.
EMA FILED ... no need for any other fluff. My boat is nearly full.
John k9uwa
william--" this year we've had 15 pr's and 8 webinars. "--yeah--really great pr's that "move the needle" NOT !!!! Give us some real news please !!!!!
mrp, I still think that some news is coming before the ASM. It is 4 weeks later than last year and there wasn't anything significant in the proxy that would have caused the delay. Keep your eyes and ears open. 🤞
ANAVEX NOW ... RIGHT NOW ... MONO-STYLE ... for LIFE ... and for ALL AGES!!!
Kb1123:
Top line data is just that "top line data" The full results and analysis of the full results takes at least months after the top line data.
GOD bless,
Steady_T,
You are correct AVXL closed at $4.07 per share.
Thank you for finding that error.
Good luck and GOD bless,
The bashers, FUDsters, and shorters tried their best with a relatively small number of shares to paint the tape at the close.
GOD bless.
How long has it been since we have received TLD ??
Um, George I show AVXL closing at $4.07.
Until Anavex gets its first approval it is still a novel approach to CNS that has never been tried. So it is viewed as high risk. The share price reflects that reality.
Once there is an approval things will change considerably, till then Anavex is still an easy target for the shorts. All 21,860,442 short shares. Which is up 570,553 shares from the last reporting period.
Short interest report on 5-24-24 short interest 21,860,442.
Fantastic demand off a manipulated option expiration trade?
Absolutely amazing justification for whatever tin foil position is espoused by the competing lunatics here.
Wake me when there is a “true” catalyst not a Company PR.
Until then 20% moves and hope to catch most of it with tight stops and decent volume.
Anavex Life Sciences Corp. Common Stock (AVXL)
AVXL $4.01 per share at the close of trading
Volume: 777,830
Expect AVXL to close at or near the high of the day, today.
Good luck and GOD bless,
Sure, Anavex is doing great. Except maybe the market cap. It's not that far off from CYDY?!?!?!?!
Who would think a company that holds the key to alleviating mankind's CNS illnesses could be priced so cheap?
You said the following:
So that all happened within a 6 month period?? It’s been over 1.5 years for the Alz data.
Ok but other than “things are coming” what concrete info have we received
The paper concerning the Alzheimer's disease Phase 2b/3 results and analysis is in the queue to be published in a peer reviewed journal. This takes time.
For example, see the amount of time it took for the fragile X paper:
Received
30 January 2021
Accepted
21 June 2021
Published
25 August 2021
Effects of the sigma-1 receptor agonist blarcamesine in a murine model of fragile X syndrome: neurobehavioral phenotypes and receptor occupancy
https://www.nature.com/articles/s41598-021-94079-7#citeas
Good luck and GOD bless,
So far this year we've had 15 pr's and 8 webinars. No lack of communication here. Company steadily making progress.
My last post got 7 emojis, which is the highest so far for me. I am honored...keep it up, WGT crowd, and keep believing in the pipe dream. Misleading is going to deliver one day (in a dream).
Keep in mind a lot of these publications are funded by big pharma. So some of them won’t want to touch Anavex.
For the record I too believe the lack of communication makes it seem like he is hiding something
Warrior...sorry, my FUD boss docks my pay if I have a typo.
Says the grand master keyboard warrier...lol...
No one needs to spread FUD to Anavex investors. Anavex is doing a great job of destroying the share price all on its own...
He has always been hiding something...
LOL...okay...
Stay steady...meaning don't take anavex...you might get dizzy...lol
I heard Missiling is heavy long the S and P Futures, short the Chinese real estate money and a very heavy silver investor. He is also a tremendous options player. Guy is sharp! He is a masterful trader/options guy. Doing it for years. He has a huge portfolio. I wish he would share some of his moves with us all., Then we could participate and lap up some of that gravy money. Somebody asked him, are you buying your own company? He just laughed and said nothing except, "honey I think I'll have another, this one on the rocks; make it a double." He then put the tip down the front of her cleavage.
Misleading has already gone on his annual Europe vacation. Wait until December to hear anything from him. In the meantime, enjoy cricket. As for peer review, he is still searching for a journal that will publish his fabricated data.
Followers
|
1065
|
Posters
|
|
Posts (Today)
|
57
|
Posts (Total)
|
460023
|
Created
|
12/18/07
|
Type
|
Free
|
Moderators RedShoulder Steady_T Bourbon_on_my_cornflakes kund mike_dotcom nidan7500 |
Anavex®Life Sciences Corp. (the “Company”) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including drug candidates to treat Alzheimer’s disease, other central nervous system (“CNS”) diseases, pain and various types of cancer. The Company’s lead compound ANAVEX®2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome.
Anavex®Life Sciences’ lead drug candidate, ANAVEX®2-73, recently completed successfully a Phase 2a clinical trial for Alzheimer’s disease. ANAVEX®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. It has also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy and others. The Michael J. Fox Foundation for Parkinson’s Research has awarded Anavex® a research grant to develop ANAVEX®2-73 for the treatment of Parkinson’s disease to fully fund a preclinical study, which could justify moving ANAVEX®2-73 into a Parkinson’s disease clinical trial. ANAVEX®3-71, also targeting sigma-1 and M1 muscarinic receptors, is a promising preclinical drug candidate demonstrating disease modifications against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also with beneficial effects on neuroinflammation and mitochondrial dysfunctions.
The Company is in preparation for ANAVEX®2-73 for a Phase 2/3, placebo-controlled trial in Alzheimer’s disease as well as a Phase 2, placebo-controlled trial in Rett syndrome, for which the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for ANAVEX®2-73 and a Phase 2, placebo-controlled trial in Parkinson’s disease.
Headquartered in New York, Anavex® Life Sciences is an American publicly traded corporation on Nasdaq quoted as AVXL
.Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |